Story

Sionna Therapeutics Shares Plunge 92% After Cystic Fibrosis Drug Fails Mid-Stage Trial

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Sionna Therapeutics Shares Plunge 92% After Cystic Fibrosis Drug Fails Mid-Stage Trial
Text size
Background

Sionna Therapeutics (NASDAQ: SION) shares plummeted 92% in trading on Monday after the company announced its lead drug candidate for cystic fibrosis, SION-719, failed to meet the main goal of a mid-stage clinical trial. The catastrophic stock decline reflects investor disappointment in a pivotal data readout for the company's pipeline.

Trial Fails to Meet Primary Endpoint

The company reported that its Phase 2a proof-of-concept study, called the PreciSION CF trial, did not achieve its key activity endpoint. The trial was designed to evaluate SION-719 as an add-on therapy to the current standard-of-care treatment, Trikafta.

The primary measure of success was a reduction in sweat chloride, a key biomarker for cystic fibrosis. According to Sionna, the trial showed a mean placebo-adjusted sweat chloride change of just -1.0 mmol/L, a result that was not statistically significant (p=0.7). Based on this outcome, the company stated it does not plan to advance SION-719 as an add-on treatment.

Company Cites Potential Confounders

Sionna, which received the topline data on Friday, said it is continuing to analyze the full results. The company noted that potential confounding factors were observed during the trial, including:

Sample IUX Markets – In-articleAd
  • Higher than anticipated variability in individual sweat chloride levels.
  • Differences in Trikafta exposure levels between the periods when patients received SION-719 versus a placebo.

Despite the efficacy failure, SION-719 was reported to be generally well-tolerated over the 14-day treatment period, with no serious adverse events. The company also reported that a separate Phase 1 trial for another candidate, SION-451, met its objectives, but it is now re-evaluating the next steps for that program in light of the SION-719 results.

Financial Position and Path Forward

For investors, the trial failure raises significant questions about the company's future. Sionna reported ending the second quarter with approximately $268.3 million in cash, cash equivalents, and marketable securities.

The company said it intends to take actions to preserve capital while it evaluates its next steps. Such measures often involve restructuring and halting spending on non-essential programs to extend the company's financial runway following a major clinical setback.

Read next

More on Stocks
Back to latest news

LATEST